markets · · marketbeat.com
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Vertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
Vertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.
- #VERX